TIMELINE
- 19 Mar 2026Retatrutide TRANSCEND-T2D-1 topline.
- Apr 2026Orforglipron, the first oral small-molecule GLP-1 agonist, approved.
- 30 Apr 2026Nature paper: five-target peptide–drug conjugate in mice.
- 21 May 2026Retatrutide TRIUMPH-1 topline: 28.3 % at 80 weeks.
- 23 Jul 2026Retatrutide TRIUMPH-2 and TRIUMPH-3 topline.
- 10 Aug 2026Yale study on AgRP neurons and GLP-1 therapy.
ENTRIES ON THIS TOPIC · 5
PAPER
Researchers at Yale report that GLP-1 therapies recruit agouti-related peptide neurons, long treated as drivers of hunger, to help maintain fat loss.
TRIAL
Between March and July 2026 Eli Lilly reported topline results from TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3. Weight reduction at 80 weeks on the 12 mg dose ranged from 20.8 % to 28.3 % depending on the population.
PAPER
Reports in 2026 describe falling physical activity among people on GLP-1 drugs, claims-data signals on bone and joint conditions with long-term use, and one-year persistence nearly doubling since 2021.
PAPER
A Nature paper describes linking the pan-PPAR agonist lanifibranor to a GLP-1/GIP peptide with a pH-sensitive linker. In mice the conjugate acted on five receptors and produced marked weight reduction.
TRIAL
April 2026 brought approval of orforglipron, the first oral small-molecule GLP-1 receptor agonist. Oral options so far produce less weight reduction than leading injectables but are easier to make and take.